Overview

An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis

Status:
Terminated
Trial end date:
2012-11-01
Target enrollment:
0
Participant gender:
All
Summary
To assess the effects of visilizumab on the safety of subsequent salvage therapies in subjects who experienced disease progression in a previous visilizumab study and subsequently received salvage therapy.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
PDL BioPharma, Inc.
Treatments:
Visilizumab
Criteria
Inclusion Criteria:

- Previous participation in a visilizumab study of IVSR-UC.

- Disease progression while enrolled in a previous visilizumab study, and subsequent
treatment with salvage therapy.

Exclusion Criteria:

- Unable to understand the purpose and risks of the study, or unwilling or unable to
provide a signed and dated informed consent.

- For U.S. sites, unwilling or unable to provide authorization to use protected health
information.